戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 arrhea) and/or alter chloride ion secretion (secretory diarrhea).
2 aganglionosis, and nonrecoverable congenital secretory diarrhea.
3 g to the MVID clinical phenotype of neonatal secretory diarrhea.
4 a, which deregulates this pathway and causes secretory diarrhea.
5 esting an important role for this pathway in secretory diarrhea.
6  a common feature of many diseases including secretory diarrhea.
7 nd can thereby be a potent target to prevent secretory diarrhea.
8 and diarrheal diseases, eg, cystic fibrosis, secretory diarrhea.
9 accumulation in a closed-loop mouse model of secretory diarrhea.
10 nockout mice are more prone to CFTR-mediated secretory diarrhea.
11 rders such as inflammatory bowel disease and secretory diarrhea.
12 -labile or heat-stable toxins which induce a secretory diarrhea.
13  pivotal role in cholera toxin (CTX)-induced secretory diarrhea.
14 ium transport are not known to be a cause of secretory diarrhea.
15 une-mediated apoptosis and limiting chloride secretory diarrhea.
16 secretomotor neurons, may lead to neurogenic secretory diarrhea.
17 m, and water in the model of chronic osmotic-secretory diarrhea.
18 brosis, whereas its hyperactivation leads to secretory diarrhea.
19 ociated diseases such as cystic fibrosis and secretory diarrheas.
20  disease and reduce intestinal fluid loss in secretory diarrheas.
21 antisecretory drugs for enterotoxin-mediated secretory diarrheas.
22 ing intestinal fluid losses in CaCC-mediated secretory diarrheas.
23 e compounds may provide a unique therapy for secretory diarrheas.
24 ay thus reduce fluid secretion in infectious secretory diarrheas.
25 g intestinal fluid loss in cholera and other secretory diarrheas.
26 y of (R)-BPO-27 for therapy of CFTR-mediated secretory diarrheas.
27 cholera and other cyclic nucleotide-mediated secretory diarrheas.
28 et in the intestinal mucosa for treatment of secretory diarrheas.
29 onditions including cholera [5, 6] and other secretory diarrheas [7] as well as polycystic kidney dis
30  conductance regulator (CFTR) contributes to secretory diarrhea, a major cause of pediatric mortality
31 mportant in the complexities associated with secretory diarrhea and also in attempting to develop tre
32 e therapeutic use in sickle cell disease and secretory diarrhea and as immunosuppressants.
33 CFTR is a potential therapeutic strategy for secretory diarrhea and autosomal dominant polycystic kid
34 neurons is basic to understanding neurogenic secretory diarrhea and constipation and therapeutic stra
35 loride channel central to the development of secretory diarrhea and cystic fibrosis.
36 F), whereas overactivity of CFTR may lead to secretory diarrhea and polycystic kidney disease.
37 he main toxicities for infusions >/=24-h are secretory diarrhea and proinflammatory syndrome.
38 table enterotoxins (STs), a leading cause of secretory diarrhea, are a major cause of morbidity and m
39        Cholera toxin (CT) causes the massive secretory diarrhea associated with epidemic cholera.
40 2/d x 3 with dose-limiting toxicity (DLT) of secretory diarrhea at 62.5 mg/kg/d x 3.
41 piridol is 50 mg/m2/d x 3 with dose-limiting secretory diarrhea at 62.5 mg/m2/d x 3.
42                                              Secretory diarrheas caused by bacterial and viral entero
43                                              Secretory diarrheas caused by bacterial enterotoxins, in
44 ntial utility of (R)-BPO-27 for treatment of secretory diarrheas caused by cholera and Escherichia co
45 toxin (ctxAB), the main cause of the profuse secretory diarrhea characteristic of cholera, are encode
46 more effective drugs for cystic fibrosis and secretory diarrhea, demonstrating the feasibility of lar
47 red rhinosinusitis, pancreatitis, and lethal secretory diarrhea (e.g. cholera).
48 ble enterotoxins (STa), which cause an acute secretory diarrhea, have been suggested to mediate their
49  were the exclusive driving force for severe secretory diarrhea in a patient with colonic pseudo-obst
50 nic Echerichia coli, is a worldwide cause of secretory diarrhea in infants and travelers.
51 lotrimazole, demonstrated ability to inhibit secretory diarrhea in laboratory studies.
52 cleotide and/or Ca(2+) signaling pathways in secretory diarrheas increases the conductance of Cl(-) c
53                                        Acute secretory diarrhea induced by infection with enterotoxig
54                                              Secretory diarrhea is caused by inhibition of intestinal
55                                              Secretory diarrhea is the leading cause of infant death
56                                              Secretory diarrhea is the leading cause of infectious di
57                                              Secretory diarrhea may be caused by binding of heat-stab
58 eptor subtype in the mediation of neurogenic secretory diarrhea, motility abnormality, and abdominal
59 nital sodium diarrhea (SCSD), an intractable secretory diarrhea of infancy.
60 y show clinical efficacy in the treatment of secretory diarrheas of diverse etiologies.
61 f Croton lechleri, is in clinical trials for secretory diarrheas of various etiologies.
62 e-phenolphthalein to produce chronic osmotic-secretory diarrhea or luminally exposed to 10 mmol/L the
63 se potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and grow
64  or increased such as in cystic fibrosis and secretory diarrhea, respectively.
65 s an AB(5) toxin responsible for the profuse secretory diarrhea resulting from Vibrio cholerae infect
66                         Enterotoxin-mediated secretory diarrheas such as cholera involve chloride sec
67 on of Cl(-) and fluid in enterotoxin-induced secretory diarrheas such as cholera.
68  render them more resistant to CFTR-mediated secretory diarrhea than Nherf2(+/+) mice in murine colit
69  study reveals an ion transport mechanism of secretory diarrhea that has not been previously apprecia
70 ovillus inclusion disease (MVID) and massive secretory diarrhea that often begins at birth.
71  of our report is to describe a patient with secretory diarrhea that was mediated by excess intestina
72 lpha-subunit activating CFTR with consequent secretory diarrhea, the AC isoform(s) involved remain un
73  of electrogenic Cl- secretion (the basis of secretory diarrhea) via apical A2b adenosine receptors.
74 mune enteropathy is characterized by chronic secretory diarrhea, villous atrophy, associated autoanti
75 tion results in intestinal fluid loss during secretory diarrheas, whereas CFTR mutations underlie cys